Although a reasonable proportion of CVD patients had other co-morbidities (HT, 77.6% and DM, 43.4%), no differences were observed in KL expression levels in PBCCs between patients who had these and those who did not (Supplementary Fig. S1). This evidence concerns the gene KL and hematocrit.